Clinical Trials on Blasts Under 20 Percent of Peripheral Blood White Cells

Total 193 results

William Shomali
Incyte Corporation

Recruiting

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Eosinophilia | Hypereosinophilic Syndrome | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Splenomegaly | Hepatomegaly | Chronic Eosinophilic Leukemia, Not Otherwise Specified | JAK2 Gene Mutation | BCR-JAK2 Fusion Protein Expression | Blasts 20 Percent or Less of Peripheral Blood White... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Pfizer

Terminated

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 30 Percent of Peripheral Blood White Cells

United States
Roswell Park Cancer Institute
Pfizer

Withdrawn

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Blasts 5 Percent or More of Peripheral Blood White Cells | Lymphoblasts... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Blasts More Than 20 Percent of Bone Marrow Nucleated Cells | Blasts More Than 20 Percent of Peripheral Blood White Cells

United States
Roswell Park Cancer Institute
Celgene

Withdrawn

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Blasts Under 5 Percent of Peripheral Blood White Cells | Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | EBV-Positive Neoplastic Cells Present | HLA-A*0201 Positive Cells Present | Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Elevated WT1

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic Leukemia | Acute Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | Acute Leukemia of Ambiguous Lineage | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia | Myelodysplastic Syndrome With Excess Blasts-1 | Mixed Phenotype Acute Leukemia | Blasts Under 5 Percent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Celgene

Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated Cells

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab in AML in Remission at High Risk for Relapse

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Blasts Under 10 Percent of Bone Marrow Nucleated Cells | Therapy-Related Myeloid Neoplasm

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Refractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent Disease

United States
Sumithira Vasu
Kiadis Pharma

Recruiting

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blasts 10 Percent or More of Bone Marrow Nucleated Cells | Allogeneic Stem Cell Transplant Recipient

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditions

United States
Boston Children's Hospital

Completed

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

AML | ALL | Biphenotypic Leukemia | Refractory Anemia | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts | Undifferentiated Leukemia | Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts | Refractory Anemia With Excess Blasts-1 (5-10% Blasts) | Refractory... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
University of Washington
National Cancer Institute (NCI)

Completed

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid Neoplasm | Chronic Myelomonocytic Leukemia-2 | Blasts 10 Percent or More of Bone Marrow Nucleated... and other conditions

United States
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.

Terminated

A Study on the Collection of Peripheral Blood Mononuclear Cells From Healthy Volunteers for the Development of Allogeneic Cellular Immunotherapy Products

Collection of Peripheral Blood Mononuclear Cells by Means of Apheresis

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...

United States
BioLineRx, Ltd.

Completed

A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers

Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)

Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | B Acute Lymphoblastic Leukemia With t(9;22)(q34... and other conditions

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Blastic Phase Chronic Myelogenous Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Refractory Anemia With Excess Blasts | Blastic Phase Chronic Myelogenous Leukemia

United States
Fred Hutchinson Cancer Center

Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Myelodysplastic Syndrome (MDS) | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Blasts Under 5 Percent of Bone Marrow...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Active, not recruiting

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Lymphoblastic Lymphoma | Childhood Acute Myeloid Leukemia in Remission | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated Cells

United States
Roswell Park Cancer Institute
Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated Cells

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
Sun Yat-sen University

Recruiting

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

China
Johann Wolfgang Goethe University Hospital

Unknown

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Philadelphia Positive Acute Lymphoblastic Leukemia | Lymphoid Blastic Phase of Chronic Myeloid Leukemia

Germany
Seagen Inc.

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Acute Myeloid Leukemia | Solid Tumors | Acute Lymphoid Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
City of Hope Medical Center

Terminated

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Masonic Cancer Center, University of Minnesota

Withdrawn

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Follicular Lymphoma | Acute Myeloid Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Mantle-Cell Lymphoma | Hematologic Malignancy | Small Lymphocytic Lymphoma | Burkitt's Lymphoma | Marginal Zone B-cell Lymphoma | Chronic Myeloproliferative... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (FIL_PTCL13)

Peripheral T-cell Lymphomas (PTCL) | PTCL-NOS | Angioimmunoblastic T-cell Lymphoma (AITL) | ALK- Anaplastic Large Cell Lymphoma (ALCL) | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin

Italy
Portola Pharmaceuticals

Withdrawn

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

AITL | Peripheral T-Cell Lymphoma (PTCL NOS) | Nodal Lymphomas of T Follicular Helper (TFH) | Follicular T-cell Lymphoma (FTCL) | ALCL | HSTCL | EATL I,II | MEITL, EATL Type II | Nasal Lymphoma
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Hematopoietic and Lymphoid Cell Neoplasm | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) | NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

United States
Samsung Medical Center
National Cancer Center, Korea; Asan Medical Center; Severance Hospital

Completed

Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma (CCRT-VIDL)

NK/T-cell Lymphoma of Nasal Cavity

Korea, Republic of
Masonic Cancer Center, University of Minnesota

Recruiting

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Myelodysplastic Syndromes | Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Anemia With Excess Blasts

United States
Goethe University

Completed

A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia

Acute Lymphoblastic Leukemia | Leukemia, Myelocytic, Acute | Chronic Myelogenous Leukemia With Crisis of Blast Cells

Germany

Clinical Trials on Blasts Under 20 Percent of Peripheral Blood White Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations